Abstract:Several classes of non-steroid 11β-HSD1 inhibitors have been developed as promising treatments for Type 2 Diabetes (T2D). Using a human 11β-HSD1 selective inhibitor as a starting point, we designed and synthesized a new class of derivatives of 1-arylsulfonyl piperidine-3-carboxamides. It was found that the large lipophilic group on the amino moiety may lead to cross-species potency towards human and mouse, allowing drug development by evaluating compounds in rodent model. By exploring structure–activity-relationship, the (R)-(+)-bornylamine derivative is identified as the most potent inhibitor of mouse enzyme 11β-HSD1 with an IC50 of 18nM. Docking studies revealed the different possible interaction modes of the S-enantiomer and R-enantiomer bound to h11β-HSD1, and explained why the S-enantiomer is more active than the R-enantiomer. Finally, two potent and isoform-selective compounds, (+)-isopinocampheylamine derivative 8m and (R)-(+)-bornylamine derivative 8l, with suitable in vitro properties, could be selected for future PK/PD evaluation in rodent models. Then, 8l was subjected a pharmacodynamics study in vivo with rodent model. It was shown that 8l have 71% and 63% inhibition in adipose and liver tissue at 1h after administration, but it was a short-acting compound displaying a significant drop in potency in the subsequent 3h. This study not only provides compounds as novel h11β-HSD1 inhibitors, but also presents structure–activity relationships for designing potent human/mouse 11β-HSD1 inhibitors suitable for in vivo evaluation in rodent models.

Discovery of adamantane ethers as inhibitors of 11β-HSD-1: Synthesis and biological evaluation

Adamantane Sulfone and Sulfonamide 11-Β-hsd1 Inhibitors

Discovery and Metabolic Stabilization of Potent and Selective 2-Amino-n-(adamant-2-yl) Acetamide 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors.

Adamantane 11-Beta-hsd-1 Inhibitors: Application of an Isocyanide Multicomponent Reaction

Design, Synthesis, and Biological Evaluation of 1,4-Diaryl-1,4-dihydropyrazines As Novel 11Β-Hsd1 Inhibitors.

Discovery of Novel Sulfonamides As Potent and Selective Inhibitors Against Human and Mouse 11Β-Hydroxysteroid Dehydrogenase Type 1

Discovery Of 2-Alkyl-1-Arylsulfonylprolinamides As 11 Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors

Discovery and structure-activity relationships of ent-Kaurene diterpenoids as potent and selective 11β-HSD1 inhibitors: potential impact in diabetes.

Progress in 11Β-Hsd1 Inhibitors for the Treatment of Metabolic Diseases: A Comprehensive Guide to Their Chemical Structure Diversity in Drug Development.

Synthesis of potent and orally efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitor HSD-016.

Mono-carbonyl Curcumin Analogues As 11Β-Hydroxysteroid Dehydrogenase 1 Inhibitors.

Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.

Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.

Discovery of ( S )- N -(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6 H )-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate

Discovery of (S)-N-(2-amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6h)-yl)ethyl)benzamide As Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate.

Discovery of Meta-Sulfamoyl N-hydroxybenzamides As HDAC8 Selective Inhibitors

Discovery of Thiadiazole Amides As Potent, S1p(3)-Sparing Agonists of Sphingosine-1-Phosphate 1 (s1p(1)) Receptor

Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity

Synthesis of Novel Curcumin Analogues for Inhibition of 11Β-Hydroxysteroid Dehydrogenase Type 1 with Anti-Diabetic Properties

Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.

N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.